Literature DB >> 71399

Heparin-induced decrease in circulating antithrombin-III.

E Marciniak, J P Gockerman.   

Abstract

Plasma-antithrombin-III (AT-III) concentrations were measured throughout therapy in 24 patients receiving continuous intravenous heparin infusion and in 2 patients treated with repeated intravenous heparin injections. In all patients, including 1 with congenital AT-III deficiency, heparin therapy was associated with a considerable progressive reduction in AT-III-binding capacity and antigenic protein. The net individual decrease in plasma-AT-III was 0-31 +/- 0-05 units/ml (normal plasma-AT-III was 1-00 units/ml) or 9-5 +/- 2-0 mg/dl and the decrease was independent of initial concentration. Plasma-AT-III returned to normal two to three days after heparin was stopped. There was no decrease in plasma-AT-III after a single dose of intravenous heparin. When present in blood for long periods heparin significantly reduced AT-III, the proteinase inhibitor that is responsible for the anticoagulant effect of this drug. The finding is very relevant to the interpretation of clinical data in patients treated with heparin and suggests that AT-III depletion may underly the thromboembolic complications sometimes encountered during heparin therapy.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 71399     DOI: 10.1016/s0140-6736(77)91429-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  31 in total

1.  Fatal or severely disabling cerebral infarction during hospitalization for stroke or transient ischemic attack.

Authors:  G W Petty; T K Tatemichi; R L Sacco; J Owen; J P Mohr
Journal:  J Neurol       Date:  1990-08       Impact factor: 4.849

Review 2.  Limitations of conventional anticoagulant therapy and the promises of non-heparin based conformational activators of antithrombin.

Authors:  Qudsia Rashid; Poonam Singh; Mohammad Abid; Mohamad Aman Jairajpuri
Journal:  J Thromb Thrombolysis       Date:  2012-08       Impact factor: 2.300

Review 3.  A systematic review of Cochrane anticoagulation reviews.

Authors:  David Keith Cundiff
Journal:  Medscape J Med       Date:  2009-01-06

4.  Risk associated with heparin withdrawal in ischaemic cerebrovascular disease.

Authors:  A Slivka; D E Levy; R H Lapinski
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-12       Impact factor: 10.154

5.  Sepsis-induced heparin resistance during extracorporeal membrane oxygenation.

Authors:  Ali Hage; Martha Louzada; Bob Kiaii
Journal:  CMAJ       Date:  2019-03-11       Impact factor: 8.262

6.  Deficiency of antithrombin III in children with hemolytic-uremic syndrome.

Authors:  B Roth; T von Lilien; B Busch; A Gillor; M Bulla
Journal:  Eur J Pediatr       Date:  1984-04       Impact factor: 3.183

7.  Relation between postoperative antithrombin III concentrations and site of operation.

Authors:  S P Gray; J A Billings; V Newton; A Olive
Journal:  J Clin Pathol       Date:  1981-06       Impact factor: 3.411

8.  Antithrombin Administration During Intravenous Heparin Anticoagulation in the Intensive Care Unit: A Single-Center Matched Retrospective Cohort Study.

Authors:  Jacob T Beyer; Kelly E Schoeppler; Giorgio Zanotti; Gregory M Weiss; Scott W Mueller; Robert MacLaren; Douglas N Fish; Tyree H Kiser
Journal:  Clin Appl Thromb Hemost       Date:  2016-09-13       Impact factor: 2.389

9.  Antithrombin III in patients on long-term oral anticoagulants.

Authors:  H Bull; I Mackie; M Brozović; D Woodings
Journal:  J Clin Pathol       Date:  1980-12       Impact factor: 3.411

10.  Acute normovolemic hemodilution does not reduce antithrombin concentration for cardiac surgery.

Authors:  Matthew Dean Linden; Mark Schneider; Wendy Naomi Erber
Journal:  J Thromb Thrombolysis       Date:  2004-06       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.